Imetelstat Sodium not checked
Geron Corporation · GRN163L
FollowEvery change as it happens, and a Monday email
Trials
4 active
7 in total · 2 in the EU
What this is
- How it works
- Oligonucleotide Telomerase Inhibitor FDA class
- How it’s given
- “imetelstat will be given intravenously at 3.55 mg/kg intravenous (IV) every 28 days (±3 days), until disease progression or unacceptable toxicity, withdrawal from treatment or end of study.”In the company’s words, NCT07939451 on ClinicalTrials.gov
- Tested for
- Myelofibrosis (2 trials), MDS (Myelodysplastic Syndrome), MDS, Myelodysplastic Syndromes
- Main trialPhase 4
- “This study is testing two doses of imetelstat in adults with lower-risk myelodysplastic syndrome, or MDS. The study will include about 100 adults in several countries. To be eligible, participants must have lower-risk MDS, need frequent red blood cell transfusions, and have already tried-or cannot use-other treatments for anemia. Participants will be randomly placed into one of two groups. One group will receive the usual dose of imetelstat, 7.1 mg/kg of body weight. The other group will receive a lower dose, 3.55 mg/kg. Both doses are given through a vein during a roughly two-hour clinic…”In the company’s words, NCT07939451 on ClinicalTrials.gov
- Other names
- GRN163L · Imetelstat
Other drugs for Myelofibrosis
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- PelabresibNovartis · Phase 3
Coming up3
- Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Jul 2030Phase 4 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovNew trial: none to Phase 4 · ClinicalTrials.gov NCT07939451
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | Jul 2030 | A Trial Evaluating Two Imetelstat Doses in Participants With Lower Risk Myelodysplastic Syndrome (MDS) | |
| Phase 3Active, not recruiting | 30 Jun 2028 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | |
| Phase 2/3Active, not recruiting | 13 Oct 2023 | Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | |
| Phase 1Active, not recruiting | Feb 2027 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | |
| Phase 2Completed | Nov 2014 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | |
| Phase 2Completed | 26 Apr 2018 | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor | |
| Phase 2Completed | 24 May 2018 | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026